Lineage Cell Therapeutics, Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 08/12/2019   Download
SEC Document
SEC Filing

Effective August 9, 2019, the Company amended and restated its bylaws to: (1) reflect its new name; (2) reflect developments in the Code, including to clarify and expressly provide that shareholder meetings may be conducted in whole or in part by electronic transmission or by electronic video screen communication as permitted by the Code; (3) include the chief executive officer position in certain provisions to reflect the Company’s current organizational structure; (4) reflect the voting standard in the Code for matters submitted to shareholders, other than the election of directors; and (5) make additional non-substantive, conforming and technical changes.